A review of linezolid: the first oxazolidinone antibiotic (Q33363226)

26 July 2017

1 reference

title

A review of linezolid: the first oxazolidinone antibiotic (English)

1 reference

26 July 2017

0 references

1 reference

3

Karl Madaras-Kelly

1 reference

26 July 2017

Dennis L Stevens

1

1 reference

PubMed ID

15482171

26 July 2017

Brian Dotter

series ordinal

2

1 reference

PubMed ID

15482171

26 July 2017

language of work or name

1 reference

1 February 2004

1 reference

Expert Review of Anti-infective Therapy

26 July 2017

1 reference

26 July 2017

2

1 reference

26 July 2017

1

1 reference

26 July 2017

51-59

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002.

26 July 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

A multicenter evaluation of linezolid antimicrobial activity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Activity of linezolid against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Activities of linezolid against rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Thrombocytopenia associated with linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Thrombocytopenia secondary to linezolid administration: what is the risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Mechanisms for linezolid-induced anemia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Serotonin syndrome and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Serotonin Syndrome after Concomitant Treatment with Linezolid and Citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.51

21 January 2018

Identifiers

DOI

10.1586/14787210.2.1.51

1 reference

26 July 2017

1 reference

PubMed ID

15482171